HMO Nutritional Composition for Infant Gastrointestinal Infection Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current solutions for preventing and treating gastrointestinal infections and inflammations in infants and young children are inadequate, as they often target specific causes and may not be effective against a broad range of pathogens, and can have side effects or be costly and difficult to deliver.
Innovation Solution
A nutritional composition comprising a specific ratio of fucosylated oligosaccharides and N-acetylated oligosaccharides, such as 2'-fucosyllactose and lacto-N-neotetraose, which acts synergistically to prevent and treat gastrointestinal infections and inflammations by boosting commensal microbiota and innate immunity, targeting pathogens and reducing their virulence.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If specific treatments or antibiotics are used to target particular pathogens, then the effectiveness against specific infections is improved, but the applicability against a broad range of pathogens deteriorates
Solution Approach 1:
The patent applies universality by using human milk oligosaccharides (HMOs) that provide broad-spectrum protection against multiple types of pathogens including viruses, bacteria, and parasites. The HMOs act as universal prebiotics that stimulate the infant's immune system and promote beneficial microbiota growth, offering protection against diverse gastrointestinal infections rather than targeting specific pathogens with narrow-spectrum treatments.
Solution Approach 2:
The patent uses HMOs as intermediary substances that mediate between the infant's immune system and pathogens. These oligosaccharides serve as decoy receptors that bind to pathogens, preventing them from attaching to intestinal cells, and also act as signaling molecules that stimulate immune cell development and function, providing indirect protection against multiple pathogen types.
2Reliability
If conventional treatments are administered to infants, then the treatment effectiveness may be improved, but side effects and treatment complexity increase
Solution Approach 1:
The patent applies self-service by using HMOs to stimulate the infant's own immune system and beneficial microbiota to fight infections. Rather than introducing external drugs that may cause side effects, the treatment empowers the infant's body to defend itself against pathogens through enhanced immune responses and colonization resistance provided by the prebiotic oligosaccharides.
Solution Approach 2:
The patent uses HMOs as safe, naturally occurring substances that can be administered without concern for accumulation or long-term side effects. These oligosaccharides are benign components of human milk that provide temporary but effective protection during the critical period when infants are most vulnerable to infections, without the need for complex monitoring or management.
3Reliability
If antibiotics are used to treat gastrointestinal infections, then the immediate symptom relief is improved, but the disruption of commensal microbiota and development of resistance occurs
Solution Approach 1:
The patent converts the concept of pathogen targeting into a beneficial approach by using HMOs that selectively support beneficial microbiota while indirectly inhibiting pathogens. The oligosaccharides serve as food for beneficial bacteria, promoting their growth and activity, which in turn provides colonization resistance against harmful pathogens without the harmful side effects of antibiotics.
Solution Approach 2:
The patent inverts the conventional approach by instead of directly killing pathogens with antibiotics, it uses HMOs to strengthen the protective factors (commensal microbiota and immune system) that naturally prevent pathogen colonization. This indirect approach achieves pathogen control while avoiding microbiota disruption and resistance development.
Data Source
Figure 1
Figure 2
AI summary
The present invention relates to a nutritional composition comprising at least one fucosylated oligosaccharide and at least one N-acetylated oligosaccharide in a particular ratio, for use in preventing and/or treating gastrointestinal infections and/or gastrointestinal inflammations in an infant or a young child.